Vertex Pharmaceuticals Inc
XMUN:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
XMUN:VX1
|
US |
|
D
|
DR Horton Inc
XMUN:HO2
|
US |
|
M
|
Marubeni Corp
OTC:MARUY
|
JP |
|
B
|
Berkshire Hathaway Inc
XMUN:BRYN
|
US |
|
Pilgrims Pride Corp
NASDAQ:PPC
|
US |
|
Tomra Systems ASA
OSE:TOM
|
NO |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 462.61 EUR with a low forecast of 275.95 EUR and a high forecast of 557.23 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
462.61
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 462.61 EUR with a low forecast of 275.95 EUR and a high forecast of 557.23 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Net Income over the next 8 years is 15%.
